Using TGF-beta2 to make stem cells less likely to be rejected by the immune system
Manipulation of MHC expression using TGF-beta2 to reduce mesenchymal stem cell immunogenicity
This study is looking at how a special protein called TGF-β2 can help make stem cells less likely to be rejected by the immune system, which could lead to better treatments for conditions caused by inflammation or immune issues.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Maryland, College Park NIH-funded |
| Lab location | 1 site (College Park, United States) |
| Project ID | NIH-10952552 on NIH RePORTER |
What this research studies
This research investigates how transforming growth factor-beta2 (TGF-β2) can be used to modify mesenchymal stem cells (MSCs) to reduce their immunogenicity, which is the likelihood of being rejected by the immune system. The approach involves treating MSCs with TGF-β2 to downregulate the expression of major histocompatibility complex (MHC) molecules, which are responsible for triggering immune responses. By understanding the signaling pathways involved, the research aims to enhance the compatibility of donor MSCs for allogeneic therapies, potentially allowing for more effective treatments for inflammatory and immune-mediated diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from inflammatory and immune-mediated diseases who may benefit from stem cell therapies.
Not a fit: Patients with conditions that do not involve immune-mediated responses or those who are not candidates for stem cell therapy may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved stem cell therapies that are less likely to be rejected by patients' immune systems.
How similar studies have performed: Previous research has shown promise in manipulating immune responses to improve stem cell therapy outcomes, indicating that this approach could be a meaningful advancement.
Where this research is happening
College Park, United States
- Univ of Maryland, College Park — College Park, United States (Active)
Researchers
- Principal investigator: Berglund, Alix K. — Univ of Maryland, College Park
- Study coordinator: Berglund, Alix K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.